Compugen (CGEN) EBITDA Margin (2009 - 2026)

Compugen recorded quarterly EBITDA Margin of 414.38% in Q1 2026, up 12.74% quarter-over-quarter from 367.56% in Q1 2025, and up 4683.0% year-over-year from 8.66% in Q1 2025.

Compugen's EBITDA Margin history runs 2 years deep, the most recent figure standing at 414.38% for Q1 2026.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -6.43%
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 38.10%
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 18.35%
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 17.24%
10 Compugen 234.03 Mn 142.28 Mn 352,000.00 414.38%

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 414.38%
Dec 31, 2025 83.23%
Sep 30, 2025 -417.40%
Jun 30, 2025 -2,006.28%
Mar 31, 2025 367.56%
Dec 31, 2024 -508.70%
Sep 30, 2024 26.24%
Jun 30, 2024 -304.33%
Mar 31, 2024 331.85%
Dec 31, 2023 53.75%
Dec 31, 2022 -47.05%
Dec 31, 2020 -454.55%
Sep 30, 2018 -42.72%
Dec 31, 2016 -16,484.91%
Sep 30, 2016 -11,381.43%
Jun 30, 2016 -1,412.90%
Mar 31, 2016 -9,538.71%
Dec 31, 2015 -8.75%
Sep 30, 2015 -3,019.21%
Jun 30, 2015 -3,117.94%
Mar 31, 2015 -1,232.36%
Dec 31, 2014 -17.02%
Sep 30, 2014 -267.35%
Jun 30, 2014 -168.94%
Mar 31, 2014 -155.23%
Dec 31, 2013 -222.99%
Sep 30, 2013 -276.86%
Jun 30, 2013 -21,450.00%
Mar 31, 2013 -2,446.91%
Dec 31, 2012 -2,866.42%
Sep 30, 2012 -3,355.56%
Dec 31, 2010 -1,210.53%
Jun 30, 2010 -117.13%
Mar 31, 2010 -2,174.40%
Dec 31, 2009 -7,804.00%
Sep 30, 2009 2,108.33%